Amylyx Pharmaceuticals Inc’s (AMLX.O) drug for amyotrophic lateral sclerosis (ALS) won support from outside advisers to the US Food and Drug Administration on Wednesday, months after the panel rejected it over issues with the test data. ALS, the cause of which is largely unknown, destroys nerve cells in the brain and spinal cord. It affects more than 31,000 patients in the United States, according to 2017 CDC data.
“ALS is fast-moving, 100% deadly, and has no meaningful treatment…a drug that extends life, whether it’s 6, 10, or 18 months, has shown more than enough evidence of efficacy,” said Ben Wallace, 41. years, who was diagnosed with ALS in 2018